Gufic Biosciences Limited
Gufic Biosciences Limited manufactures and markets active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services in India, Africa, Asia, Europe, Australia, North America, and South America. The company manufactures APIs and bulk drugs, such as antifungals, anaethetics, immuno suppressants, anginotensin receptor blocker, and intermediates for antifungals. It also manufact… Read more
Market Cap & Net Worth: Gufic Biosciences Limited (GUFICBIO)
Gufic Biosciences Limited (NSE:GUFICBIO) has a market capitalization of $332.79 Million (₹28.82 Billion) as of March 18, 2026. Listed on the NSE stock exchange, this India-based company holds position #18878 globally and #911 in its home market, demonstrating a 5.08% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Gufic Biosciences Limited's stock price ₹287.40 by its total outstanding shares 100282506 (100.28 Million).
Gufic Biosciences Limited Market Cap History: 2015 to 2026
Gufic Biosciences Limited's market capitalization history from 2015 to 2026. Data shows growth from $63.27 Million to $332.79 Million (20.85% CAGR).
Index Memberships
Gufic Biosciences Limited is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NIFTY MICROCAP 250
NIFTYMICROCAP250
|
$69.23 Billion | 0.12% | #187 of 250 |
|
NIFTY TOTAL MARKET
NIFTYTOTALMKT
|
$1.39 Trillion | 0.01% | #629 of 750 |
Weight: Gufic Biosciences Limited's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Gufic Biosciences Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Gufic Biosciences Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.05x
Gufic Biosciences Limited's market cap is 0.05 times its annual revenue
1.11x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
0.56x
Gufic Biosciences Limited's market cap is 0.56 times its annual earnings
11.98x
Lower than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $61.33 Million | $1.96 Billion | $73.24 Million | 0.03x | 0.84x |
| 2017 | $146.23 Million | $2.40 Billion | $90.21 Million | 0.06x | 1.62x |
| 2018 | $107.85 Million | $3.01 Billion | $164.76 Million | 0.04x | 0.65x |
| 2019 | $69.76 Million | $3.51 Billion | $219.41 Million | 0.02x | 0.32x |
| 2020 | $135.26 Million | $3.79 Billion | $226.88 Million | 0.04x | 0.60x |
| 2021 | $274.70 Million | $4.88 Billion | $442.32 Million | 0.06x | 0.62x |
| 2022 | $262.06 Million | $7.79 Billion | $958.40 Million | 0.03x | 0.27x |
| 2023 | $366.34 Million | $6.91 Billion | $797.05 Million | 0.05x | 0.46x |
| 2024 | $527.21 Million | $8.07 Billion | $861.36 Million | 0.07x | 0.61x |
| 2025 | $389.07 Million | $8.20 Billion | $696.50 Million | 0.05x | 0.56x |
Competitor Companies of GUFICBIO by Market Capitalization
Companies near Gufic Biosciences Limited in the global market cap rankings as of March 18, 2026.
Key companies related to Gufic Biosciences Limited by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #423 globally with a market cap of $51.97 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #455 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #719 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #423 | Zoetis Inc | NYSE:ZTS | $51.97 Billion | $118.15 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.46 |
| #455 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #719 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Gufic Biosciences Limited Historical Marketcap From 2015 to 2026
Between 2015 and today, Gufic Biosciences Limited's market cap moved from $63.27 Million to $ 332.79 Million, with a yearly change of 20.85%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₹332.79 Million | -14.46% |
| 2025 | ₹389.07 Million | -26.20% |
| 2024 | ₹527.21 Million | +43.91% |
| 2023 | ₹366.34 Million | +39.79% |
| 2022 | ₹262.06 Million | -4.60% |
| 2021 | ₹274.70 Million | +103.09% |
| 2020 | ₹135.26 Million | +93.88% |
| 2019 | ₹69.76 Million | -35.32% |
| 2018 | ₹107.85 Million | -26.24% |
| 2017 | ₹146.23 Million | +138.43% |
| 2016 | ₹61.33 Million | -3.06% |
| 2015 | ₹63.27 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of Gufic Biosciences Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $332.79 Million USD |
| MoneyControl | $332.79 Million USD |
| MarketWatch | $332.79 Million USD |
| marketcap.company | $332.79 Million USD |
| Reuters | $332.79 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.